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Abstract
Background: Physicians reading the medical literature attempt to determine whether research
studies are valid. However, articles with negative results may not provide sufficient information to
allow physicians to properly assess validity.
Methods: We analyzed all original research articles with negative results published in 1997 in the
weekly journals BMJ, JAMA, Lancet, and New England Journal of Medicine as well as those published
in the 1997 and 1998 issues of the bimonthly Annals of Internal Medicine (N = 234). Our primary
objective was to quantify the proportion of studies with negative results that comment on power
and present confidence intervals. Secondary outcomes were to quantify the proportion of these
studies with a specified effect size and a defined primary outcome. Stratified analyses by study
design were also performed.
Results: Only 30% of the articles with negative results comment on power. The reporting of
power (range: 15%-52%) and confidence intervals (range: 55–81%) varied significantly among
journals. Observational studies of etiology/risk factors addressed power less frequently (15%, 95%
CI, 8–21%) than did clinical trials (56%, 95% CI, 46–67%, p < 0.001). While 87% of articles with
power calculations specified an effect size the authors sought to detect, a minority gave a rationale
for the effect size. Only half of the studies with negative results clearly defined a primary outcome.
Conclusion:  Prominent medical journals often provide insufficient information to assess the
validity of studies with negative results.
Background
Physicians are faced with the challenge of assessing
whether the conclusions of research studies are valid.
Power, the probability that a study will detect an effect of
a specified size, is analogous to the sensitivity of a diag-
nostic test. [1] Just as a negative result does not rule out
disease when the test applied has low sensitivity, a nega-
tive study with inadequate power cannot disprove a re-
search hypothesis. Power/sample size calculations play an
important role in study planning, give readers an idea of
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the adequacy of the investigation, and help readers assess
the validity of studies with negative results. [2–4] Effect
size (delta) is a critical component of power calculations.
Investigators choose from a wide range of possible deltas
when calculating sample size. Clinicians and investigators
also often struggle to determine what effect size is reason-
able to expect.[2,5–8] Consequently, it is important for
investigators to report the effect size they wish to detect.
However, this is often neglected.[8]
Sample size calculations alone are insufficient for the in-
terpretation of studies with negative results; power and
confidence intervals compliment each other and should
both be reported.[6,9] Confidence intervals take into ac-
count the data actually collected, define the upper and
lower range consistent with a study's data, provide an es-
timate of precision, and can give readers some indication
of the clinical significance of the results. [10–13]
Our work adds to the literature in several ways. Several au-
thors have found that many randomized controlled trials
were underpowered, or had an unacceptable risk of miss-
ing an important effect due to inadequate sample size.
[14–21] Because power calculations are often complicat-
ed,[21] many readers are unlikely to have the statistical so-
phistication necessary to perform a power analysis.
Therefore, we were interested in whether articles provided
information necessary for readers to assess the validity of
studies with negative results. We looked for evidence of
power/sample size calculations and effect size. In addi-
tion, unlike prior work, we examined studies for docu-
mentation of confidence intervals.[22] Finally, because
the calculation of sample size is applicable to all compar-
ative studies, we did not limit our study to randomized
controlled trials.[23]
Our primary objective was to quantify the proportion of
studies with negative results within prominent general
medical journals[24] that comment on power and present
confidence intervals. Secondary outcomes were to quanti-
fy the proportion of these studies with a specified delta
and a defined primary outcome.
Methods
All articles from the 1997 issues of the British Medical
Journal (BMJ), Journal of the American Medical Associa-
tion (JAMA), Lancet, and the New England Journal of
Medicine (NEJM) were reviewed. Because the Annals of
Internal Medicine (Annals) is published bimonthly, all ar-
ticles from 1997 and 1998 were reviewed so as to include
a comparable number of articles. One investigator (RSH)
manually searched the journals and reviewed all articles
for eligibility. Review articles, meta-analyses, modeling
studies, decision and cost-effective analyses, case reports,
editorials, letters, and studies without inferential statistics
(i.e. descriptive studies) were excluded. Equivalence trials
(studies designed to show equivalent efficacy of treat-
ments) were included because power analysis, confidence
intervals, and delta are particularly important to their de-
sign. Methodological issues involved in the design and
analysis of these studies have been described else-
where.[25,26]
Articles were classified as having negative results if 1) the
primary outcome(s) was not statistically significant (i.e.
the article had an explicit statement that the comparison
between two groups did not reach statistical significance)
or 2) in those articles with no primary outcome(s), any of
the first three outcomes were not statistically significant.
Other outcomes were not evaluated. A second author
(TAE) reviewed the full text of a simple random sample of
50 articles and the kappa statistic was calculated to assess
the intraobserver variability for our classification scheme.
We examined articles to see if the authors named a prima-
ry outcome variable. We employed a decision rule, modi-
fied from Moher and colleagues, to define the primary
outcome in those articles where none was specified.[19] If
an article reported a sample size calculation, this was as-
sumed to be the primary outcome.[27] If calculations
were not performed, a total of three outcomes, if present,
were examined. In those articles with multiple outcomes
and none defined as primary, the three outcomes evaluat-
ed were the first three listed in the abstract (or result sec-
tion if less than three outcomes were listed in the
abstract).
The full text of included articles was systemically re-
viewed. Data was abstracted by a single author (RSH) and
recorded in standardized fashion. Information was re-
corded on whether the article had a primary outcome(s),
commented on power, sample size calculations, and con-
fidence intervals pertaining to the outcomes evaluated, a
projected delta, and a reason for this delta. A paper was
given credit for addressing power if sample size calcula-
tions or comments on power/sample size were present.
Power, sample size calculations, and confidence intervals
could pertain to any one of the three outcomes evaluated
and was not necessary for all outcomes.
Comparisons were made across journals by Chi-square
analysis. We also assessed articles for comment on power
and/or presentation of confidence intervals while stratify-
ing by study design (clinical trials, observational studies
of etiology/risk factors, screening/diagnosis, prognosis,
and other). Responses were summarized as proportions
and 95% confidence intervals. All data was analyzed using
STATA 6.0 (Stata Corp., College Station, TX).Journal of Negative Results in BioMedicine 2002, 1 http://www.jnrbm.com/content/1/1/1
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Results
One thousand thirty eight articles were eligible for analy-
sis. Two hundred thirty four (23%) were classified as neg-
ative. There was good agreement between observers in the
classification of articles (k = 0.74). The percent of negative
articles per journal was: Annals 20% (41/203), BMJ 22%
(57/256), JAMA 23% (44/191), Lancet 22% (46/205),
and NEJM 25% (46/183) (p = 0.857).
Thirty percent (70/234) of studies with negative results
had comments on power and/or sample size calculations.
Seventy three percent (171/234) included confidence in-
tervals. The reporting of power (range: 15%-52%) and
confidence intervals (range: 55–81%) varied significantly
among journals. Twenty two percent of the studies includ-
ed both power/sample size calculations and confidence
intervals. There existed significant variation between jour-
nals in the reporting of power/sample size calculations
and confidence intervals (Table 1). Because clinical trials
(n = 87) and observational studies of etiology/risk factors
(n = 109) were the predominant study designs (84% of
the negative studies), articles with other study designs
were not examined further. Fifty six percent (95% CI, 46–
67%) of negative clinical trials and 15% (95% CI, 8–21%)
of negative observational risk factor/etiology studies ad-
dressed power/sample size (p < 0.001). For reporting con-
fidence intervals, the corresponding percentages were
79% (95% CI, 71–87%) and 75% (95% CI, 65–84%), re-
spectively (p = 0.489).
Of the negative articles including information about sam-
ple size, 87% (61/70) specified a delta or the effect size
that the authors sought to detect. A minority, 43% (26/
61), explained the rationale behind the delta chosen. Of
these, 77% (20/26) cited references or pilot studies to sup-
port their rationale.
Only 52% (122/234) of articles with negative results had
a clearly defined primary outcome(s).
Discussion
Many articles underreport power/sample size calculations
and confidence intervals. Significant variation exists
among journals. Our work demonstrates that power was
reported more often in clinical trials than in observational
studies of etiology/risk factors. Investigators involved in
randomized clinical trials may be more familiar with the
importance of power and sample size calculation.[28] Al-
so, investigators conducting observational studies often
do not have the ability to determine sample size prior to
beginning their work. Most articles with sample size cal-
culations reported a projected effect size, but only a mi-
nority shared the rationale behind this delta and even less
provided empiric evidence to support the rationale.
While this manuscript describes an analysis of a large
body of studies with negative results, several limitations
must be considered. First, although most negative studies
did not list power/sample size calculation, we cannot be
certain this had not been performed a priori. It is also pos-
sible that, for the sake of brevity, authors and/or editors
omitted power/sample size calculations from the final text
when preparing manuscripts for submission. While it is
possible these calculations were done but not reported,
this may not be the case.[29] Second, our definition of a
negative study may seem unduly broad. We examined
three outcomes in order to classify articles because articles
frequently report several outcomes, often with none de-
fined as primary. [30–33] Previous authors, limiting their
work to randomized controlled trials, who have encoun-
tered multiple outcomes have defined the primary out-
come as "the most clinically important"[19] or the
outcome that was the "primary focus of the article".[20]
These outcomes are often not possible to discern in obser-
vational studies. Nonetheless, our results may represent a
best-case scenario given the publication bias against arti-
cles with negative results and the fact that we examined
the more prominent general medical journals.[34]
Table 1: Negative articles addressing power/sample size and confidence intervals
Journal Power/Sample Size* Confidence Intervals† Power/Sample Size and Confidence 
Intervals*
n (%, 95% CI)
Annals 6/41 (15, 3–26) 33/41 (80, 68–93) 5/41 (12, 2–23)
BMJ 11/57 (19, 9–30) 46/57 (81, 70–91) 10/57 (18, 7–28)
JAMA 10/44 (23, 10–36) 24/44 (55, 39–70) 3/44 (7, 0–15)
Lancet 24/46 (52, 37–67) 34/46 (74, 61–87) 20/46 (43, 29–58)
NEJM 19/46 (41, 27–56) 34/46 (74, 61–87) 13/46 (28, 15–42)
Total 70/234 (30, 24–36) 171/234 (73, 67–79) 51/234 (22, 16–27)
* P < 0.001 † P = 0.038Journal of Negative Results in BioMedicine 2002, 1 http://www.jnrbm.com/content/1/1/1
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Conclusions
In summary, this study demonstrates that prominent
medical journals often provide insufficient information to
assess the validity of studies with negative results. Authors
and journal editors need to include this information so
readers can be informed consumers of the medical litera-
ture.
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